Lipisense
Severe Hypertriglyceridemia (SHTG) / Dyslipidemia
Phase IIActive - Topline data expected H2 2025
Key Facts
Indication
Severe Hypertriglyceridemia (SHTG) / Dyslipidemia
Phase
Phase II
Status
Active - Topline data expected H2 2025
Company
About Lipigon Pharmaceuticals
Lipigon Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class drugs for lipid metabolism disorders and related cardiometabolic diseases. Its strategy leverages deep target validation expertise and external platform partnerships to advance a pipeline of RNA-based and small molecule therapeutics. Key achievements include a Phase II-ready lead asset (Lipisense), strategic partnerships in China (Leaderna) and for discovery (HitGen), and a foundation in renowned Umeå University research.
View full company profile